Inhibition of the anti-apoptotic protein B-cell lymphoma-2 (BCL-2), often over-expressed in hematological malignancies, can induce apoptosis. Venetoclax is an example of a BCL-2 inhibitor and is used in the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL).